News & Updates

People living with HIV (PWH) may soon benefit from a once-weekly treatment regimen instead of the standard daily antiretroviral therapy to manage their condition. Two recent phase III trials, ISLEND-1 and -2, have shown the efficacy of islatravir/lenacapavir (ISL/LEN) vs bictegravir/emtricitabine/tenofovir/alafenamide (B/F/TAF) or standard of care (SOC).

Active cycle of breathing technique (ACBT) and walking with huffing demonstrate similar efficacy in improving sputum expectoration and health-related quality of life (HRQOL) in hospitalized adults with exacerbation of bronchiectasis, a study has found.

Patients with rheumatoid arthritis (RA) also suffer several comorbidities, the most common being circulatory and metabolic disorders, according to a Bangladesh study.

In a prespecified secondary analysis of the phase III FLOW trial, semaglutide reduces the risk of serious infections and COVID-19 events in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD).